Literature DB >> 20071153

Molecular mechanisms of fosfomycin resistance in clinical isolates of Escherichia coli.

Sho Takahata1, Takashi Ida, Toru Hiraishi, Shiro Sakakibara, Kazunori Maebashi, Shinichi Terada, Tetsuro Muratani, Tetsuro Matsumoto, Chikara Nakahama, Kazunori Tomono.   

Abstract

To clarify the molecular mechanisms of fosfomycin resistance in clinical isolates of Escherichia coli, the murA, glpT, uhpT, uhpA, ptsI and cyaA genes were sequenced from six fosfomycin-resistant isolates. Two strains were found to harbour a mutation in the murA gene that leads to an amino acid substitution (Asp369Asn or Leu370Ile) in the target protein. The remaining four strains carried specific mutations in the glpT gene; one strain possessed a mutation and the other three strains possessed truncated versions of the GlpT transporter owing either to the presence of insertion sequences or a deletion in the coding region of the gene. Two of the strains with truncated GlpT had also lost the entire uhpT gene, which encodes another fosfomycin transporter. Uptake of specific substrates for the transporters was either totally blocked or reduced in strains possessing truncated forms of GlpT or those lacking the uhpT gene. Escherichia coli strains expressing an amino-acid-substituted MurA were at least eight-fold more resistant to fosfomycin than the strain overproducing wild-type MurA. In conclusion, novel amino acid substitutions in MurA or the loss of function of transporters were identified as mechanisms of fosfomycin resistance in clinical isolates of E. coli. (c) 2009 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20071153     DOI: 10.1016/j.ijantimicag.2009.11.011

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  67 in total

1.  First report of a clinical, multidrug-resistant Enterobacteriaceae isolate coharboring fosfomycin resistance gene fosA3 and carbapenemase gene blaKPC-2 on the same transposon, Tn1721.

Authors:  Gang Li; Ying Zhang; Dexi Bi; Pinghua Shen; Fuqi Ai; Hong Liu; Yueru Tian; Yiming Ma; Bei Wang; Kumar Rajakumar; Hong-Yu Ou; Xiaofei Jiang
Journal:  Antimicrob Agents Chemother       Date:  2014-11-03       Impact factor: 5.191

2.  Dissemination of the fosfomycin resistance gene fosA3 with CTX-M β-lactamase genes and rmtB carried on IncFII plasmids among Escherichia coli isolates from pets in China.

Authors:  Jianxia Hou; Xianhui Huang; Yuting Deng; Liangying He; Tong Yang; Zhenling Zeng; Zhangliu Chen; Jian-Hua Liu
Journal:  Antimicrob Agents Chemother       Date:  2012-01-09       Impact factor: 5.191

3.  Genomewide overexpression screen for fosfomycin resistance in Escherichia coli: MurA confers clinical resistance at low fitness cost.

Authors:  Alejandro Couce; Alejandra Briales; Alexandro Rodríguez-Rojas; Coloma Costas; Alvaro Pascual; Jesús Blázquez
Journal:  Antimicrob Agents Chemother       Date:  2012-02-27       Impact factor: 5.191

Review 4.  The structural biology of enzymes involved in natural product glycosylation.

Authors:  Shanteri Singh; George N Phillips; Jon S Thorson
Journal:  Nat Prod Rep       Date:  2012-06-12       Impact factor: 13.423

5.  Prevalence of fosfomycin resistance among CTX-M-producing Escherichia coli clinical isolates in Japan and identification of novel plasmid-mediated fosfomycin-modifying enzymes.

Authors:  Jun-ichi Wachino; Kunikazu Yamane; Satowa Suzuki; Kouji Kimura; Yoshichika Arakawa
Journal:  Antimicrob Agents Chemother       Date:  2010-04-19       Impact factor: 5.191

6.  Ex Vivo Urinary Bactericidal Activity and Urinary Pharmacodynamics of Fosfomycin after Two Repeated Dosing Regimens of Oral Fosfomycin Tromethamine in Healthy Adult Subjects.

Authors:  E Wenzler; K M Meyer; S C Bleasdale; M Sikka; R E Mendes; K L Bunnell; M Finnemeyer; S L Rosenkranz; L H Danziger; K A Rodvold
Journal:  Antimicrob Agents Chemother       Date:  2020-01-27       Impact factor: 5.191

7.  Efficacy of fosfomycin in experimental osteomyelitis due to methicillin-resistant Staphylococcus aureus.

Authors:  W Poeppl; S Tobudic; T Lingscheid; R Plasenzotti; N Kozakowski; A Georgopoulos; H Burgmann
Journal:  Antimicrob Agents Chemother       Date:  2010-11-22       Impact factor: 5.191

Review 8.  Resistance to antibiotics targeted to the bacterial cell wall.

Authors:  I Nikolaidis; S Favini-Stabile; A Dessen
Journal:  Protein Sci       Date:  2014-01-17       Impact factor: 6.725

9.  Efficacy of fosfomycin compared to vancomycin in treatment of implant-associated chronic methicillin-resistant Staphylococcus aureus osteomyelitis in rats.

Authors:  Wolfgang Poeppl; Tilman Lingscheid; Dominik Bernitzky; Uwe Y Schwarze; Oliver Donath; Thomas Perkmann; Nicolas Kozakowski; Roberto Plasenzotti; Gottfried Reznicek; Heinz Burgmann
Journal:  Antimicrob Agents Chemother       Date:  2014-06-16       Impact factor: 5.191

10.  Organoarsenicals inhibit bacterial peptidoglycan biosynthesis by targeting the essential enzyme MurA.

Authors:  Luis D Garbinski; Barry P Rosen; Masafumi Yoshinaga
Journal:  Chemosphere       Date:  2020-04-27       Impact factor: 7.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.